Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 14 | 692 | 44% |
| 2020 | 12 | 519 | 46% |
| 2021 | 11 | 502 | 49% |
| 2022 | 13 | 623 | 51% |
| 2023 | 22 | 1,161 | 53% |
| 2024 | 23 | 1,632 | 54% |
| 2025 from claims | – | 1,920 1,762–2,032 | 55% |
| 2026 forecast | – | 2,116 1,862–2,442 | 55% |
| 2027 forecast | – | 2,324 1,987–2,769 | 56% |
| 2028 forecast | – | 2,551 2,129–3,124 | 56% |
| 2029 forecast | – | 2,801 2,287–3,512 | 57% |
| 2030 forecast | – | 3,074 2,463–3,940 | 57% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 69% of the cases CMS names in Arizona; 14 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 1% inpatient hospital, 9% hospital outpatient, 83% surgery center, 8% office. The share outside the hospital has moved +21 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~2,100 | ~15 | ~140 | ~1,800 | ~150 |
| 2027 · ~2,300 | ~16 | ~120 | ~2,000 | ~160 |
| 2028 · ~2,600 | ~18 | ~120 | ~2,200 | ~180 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 88% (83% in 2025), hospital outpatient about 5% (9% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 35 | 2,932+9.5%/yr | +9.5%/yr | 0.8 | 78% | 6,310 in 2030+14%/yr |
| Washington | 8 | 573+7.4%/yr | +7.4%/yr | 0.7 | 55% | 1,090 in 2030+11%/yr |
| Colorado | 10 | 515+13%/yr | +13%/yr | 1.0 | 55% | 1,080 in 2030+13%/yr |
| Idaho | 4 | 403+11%/yr | +11%/yr | 1.8 | 20% | 790 in 2030+12%/yr |
| Oregon | 4 | 325+4.4%/yr | +4.4%/yr | 0.7 | 91% | 1,740 in 2030+32%/yr |
| Nevada | 2 | 316−0.6%/yr | −0.6%/yr | 1.0 | 71% | 550 in 2030+9.6%/yr |
| Utah | 1 | 290+14%/yr | +14%/yr | 1.2 | 60% | 570 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 185 | 17,395+0.3%/yr | +0.3%/yr | 22.42.7× | 93% | 19,600 in 2030+2%/yr |
| Spinal cord & DRG stimulation | 28 | 930+0.9%/yr | +0.9%/yr | 1.22.2× | 78% | 1,060 in 2030+2.2%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
Nalu Medical leads with 69% of company spending on these surgeons in 2025, +14 pts on 2024.
In 2025, 9 companies reported engagement with Arizona’s surgeons worth $264K in consulting, speaking, meals and travel tied to these products, about $11K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.